Navigation Links
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference

SAN FRANCISCO, Nov. 2 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today presented data from its phase 2 clinical trial of XL784 in subjects with albuminuria due to diabetic nephropathy. XL784 is a small molecule inhibitor of ADAM-10 and MMP-2, metalloprotease enzymes that may play a role in the pathogenesis of diabetic nephropathy and renal fibrosis. The data were presented during a poster session (Abstract/Poster PO1030) at the American Society of Nephrology Renal Week 2007 meeting in San Francisco. The company previously announced that the clinical trial did not meet its primary endpoint.

125 subjects were enrolled into this randomized, double-blind, placebo-controlled study. XL784 (200mg once daily for 12 weeks) was compared to placebo in subjects with macro-albuminuria who were being treated concurrently with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB).

The primary endpoint was the reduction from baseline in the urinary albumin to creatinine ratio (ACR) at Week 12. Proteinuria, the presence of excess protein in the urine, is an indicator of renal disease. Albumin excretion is a risk factor for kidney failure, stroke and cardiovascular and all-cause mortality, particularly in patients with diabetes and/or hypertension. Nephropathy (kidney disease) is a common problem in diabetic patients, often leading to the need for hemodialysis or kidney transplant.

After 12 weeks of treatment with XL784 the baseline normalized ACR (end of treatment/baseline ACR) in the XL784 group was 9.9% lower than that in the placebo group (not significant). There was a clinically relevant mean ACR reduction from baseline of 23% (p=0.0027) in subjects randomized to XL784. The change in glomerular filtration rate (GFR) at Week 12 was -2.5 ml/min/1.73m2 in the XL784 group and -6.2 ml/min/1.73m2 in the placebo group (p=0.077).

In an exploratory analysis, subjects were stratified according to dose of ACEi and/or ARB received (as a percentage of the maximum FDA recommended dose). The benefit of XL784 compared to placebo increased with increasing dose of ACEi and/or ARB. In the subgroup of subjects treated with maximum recommended doses of ACEi and/or ARB, the difference between XL784 and placebo was 23% (p=0.13) for the primary analysis population.

XL784 was generally well-tolerated, with fewer subjects reporting adverse events in the XL784 group (77%) than in the placebo group (85%). Serious adverse events (SAEs) were reported by 9.5% of subjects in the XL784 group and by 11% of subjects in the placebo group. No SAEs in the XL784 group were considered to be related to study drug.

"We are pleased to report the data from the XL784 trial in patients with diabetic nephropathy," said George A. Scangos, PhD, president and chief executive officer of Exelixis. "While the trial did not meet its primary endpoint, various subgroup analyses suggest that the compound may have the potential to benefit patients with this disease. We submitted the XL784 data package to GSK on October 22, 2007 and expect to communicate future plans for XL784 once GSK has reached a decision on its interest in further developing the compound."

The previously announced briefing to be held today in conjunction with the presentation of the data for XL784 has been cancelled. However, we expect to discuss the data during the live webcast of our third quarter financial results and general business updates to be held on Monday, November 5, 2007 at 2:00 p.m. PST/5:00 p.m. EST. The webcast may be accessed in the Event Calendar page under Investors at In addition, we will discuss the data for XL784 at our Third Annual R&D Day on December 5, 2007 to be held in New York.

About XL784

XL784 is the first small molecule compound developed by Exelixis using its proprietary drug discovery engine. The compound is a potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential safety and efficacy of XL784. Words such as "may," "expect," "suggest," "potentially" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the results of any failure of XL784 to demonstrate safety and efficacy in clinical testing, risks related to Exelixis' arrangement with SEI and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 ... the addition of the "2016 Future Horizons ... Monitoring (TDM) Market: Supplier Shares, Country Segment Forecasts, ... offering. --> ... comprehensive analysis of the Japanese therapeutic drug monitoring ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... ... Dr. Thomas Dunlap and Dr. Patrick Coleman , cardiologist ... Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , co-hosted the ... ways and require time-critical intervention to avoid large area heart damage and progressive infections ...
(Date:11/26/2015)... ... 2015 , ... Patients at Serenity Point Recovery, a holistic ... Thanksgiving Day to share the things that they are most grateful for today. ... channel, patients displayed what they wrote on index cards, describing the things that ...
(Date:11/26/2015)... ... 26, 2015 , ... Somu Sivaramakrishnan announced today that he ... now offers travelers, value and care based Travel Services, including exclusive pricing on ... as, cabin upgrades and special amenities such as, shore excursions, discounted fares, travel ...
(Date:11/26/2015)... ... November 26, 2015 , ... PRMA Plastic Surgery is updating their ... surgeons performed their 6,000th free flap breast reconstruction surgery! , “What an accomplishment for ... excited to rebuild lives and it’s an honor to have served all of these ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... wellness consultation, has collaborated with Women’s Web – an online resource for ... topics on mental and emotional well-being relationship, life balance, stress, professional development, ...
Breaking Medicine News(10 mins):